title: Authors' Response.
authors.affiliation: Hospital Universitario Salamanca, Instituto Biosanitario De Salamanca (IBSAL), Spain.
authors.forename: María-Victoria
authors.initials: MV
authors.lastname: Mateos
authors.affiliation: Takeda Pharmaceuticals International Co., Cambridge, Massachusetts.
authors.forename: Hongliang
authors.initials: H
authors.lastname: Shi
authors.affiliation: Centro Investigación Medica Aplicada, Clinica Universidad De Navarra, Pamplona, Spain.
authors.forename: Jesús F
authors.initials: JF
authors.lastname: San Miguel
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality*; D011719:Pyrazines / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D001897:Boronic Acids; D011719:Pyrazines